The BioMed X Institute has launched a new global call for research proposals in collaboration with Boehringer Ingelheim.

The Company plans to continue to showcase measurable results from initiatives in development, operations, and M&A activity as ...

Strategic acquisition marks significant step to establish pan-European footprint and deepens expertise in oncology and early-phase biotech clinical trials.

Accropeutics reports positive data from phase 2 trial of AC-201, an oral, selective TYK2/JAK1 inhibitor, to treat moderate-to-severe plaque psoriasis: New York Thursday, May 22, 2 ...

Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding ...

Dr. Aaron Carrithers brings a founder’s mindset and extensive firsthand experience, guiding biotech teams through complicated ...

Plus: Rockville man arrested for filming woman in fitting room at Montgomery mall; Montgomery College launches cybersecurity ...

Tucked away on the north edge of Jacksonville, surrounded by farm fields, sits a large facility where a small team assembles ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Mamaearth parent Honasa Consumer, GMR Airports, Emcure Pharma among others will also announce their quarterly results on ...

Sanofi (NASDAQ:SNY) has announced a deal to acquire Vigil Neuroscience, a clinical-stage biotech company, for around $470 ...

AmplifyBio faces a lawsuit for allegedly violating layoff notification laws after closing its central Ohio facilities on April 4.